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Abstract
Background: In a previous Phase 1/2b malaria vaccine trial testing the 3D7 isoform of the malaria vaccine candidate
Merozoite surface protein 2 (MSP2), parasite densities in children were reduced by 62%. However, breakthrough
parasitemias were disproportionately of the alternate dimorphic form of MSP2, the FC27 genotype. We therefore undertook
a dose-escalating, double-blinded, placebo-controlled Phase 1 trial in healthy, malaria-naı ¨ve adults of MSP2-C1, a vaccine
containing recombinant forms of the two families of msp2 alleles, 3D7 and FC27 (EcMSP2-3D7 and EcMSP2-FC27),
formulated in equal amounts with MontanideH ISA 720 as a water-in-oil emulsion.
Methodology/Principal Findings: The trial was designed to include three dose cohorts (10, 40, and 80 mg), each with twelve
subjects receiving the vaccine and three control subjects receiving MontanideH ISA 720 adjuvant emulsion alone, in a
schedule of three doses at 12-week intervals. Due to unexpected local reactogenicity and concern regarding vaccine
stability, the trial was terminated after the second immunisation of the cohort receiving the 40 mg dose; no subjects
received the 80 mg dose. Immunization induced significant IgG responses to both isoforms of MSP2 in the 10 mg and 40 mg
dose cohorts, with antibody levels by ELISA higher in the 40 mg cohort. Vaccine-induced antibodies recognised native
protein by Western blots of parasite protein extracts and by immunofluorescence microscopy. Although the induced anti-
MSP2 antibodies did not directly inhibit parasite growth in vitro, IgG from the majority of individuals tested caused
significant antibody-dependent cellular inhibition (ADCI) of parasite growth.
Conclusions/Significance: As the majority of subjects vaccinated with MSP2-C1 developed an antibody responses to both
forms of MSP2, and that these antibodies mediated ADCI provide further support for MSP2 as a malaria vaccine candidate.
However, in view of the reactogenicity of this formulation, further clinical development of MSP2-C1 will require formulation
of MSP2 in an alternative adjuvant.
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Introduction
Half of the world’s population is at risk of malaria, with an
estimated 225 million cases occurring in 2009, leading to an
estimated 863,000 million deaths [1]. Most malaria cases occur in
Africa, with 85% of an estimated 781,000 deaths in children under
five years of age due to Plasmodium falciparum malaria [1]. Although
significant advances have been made in the control of malaria
through the deployment of insecticide-treated bed nets and
artemisinin combination therapy (ACT) [1], the growing threat
of drug resistance in malaria parasites [2] and the limited choice of
insecticides necessitate the development of new tools to reduce the
morbidity and mortality caused by this disease. A Phase 3 trial of
the pre-erythrocytic circumsporozoite protein (CSP) vaccine
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first licensed malaria vaccine. (ClinicalTrials.gov Identifier:
NCT00866619). However, this vaccine is unlikely to confer
complete protection. For this reason the continued clinical
development of asexual blood-stage antigens as complementary
or alternative vaccine components, remains a priority.
Of the life-cycle stages of the malaria parasite present in the
blood that could be targeted by vaccine-induced immune
responses, the merozoite has been the focus of most research.
This is the life-cycle stage released when the infected erythrocyte
ruptures, and is present only transiently in the blood before it
invades another erythrocyte. Early experimental data demonstrat-
ing effective vaccination with whole merozoite extracts was
followed by the identification of a number of important merozoite
surface proteins, some of which remain vaccine candidates. These
include Merozoite Surface Protein 1 (MSP1), Apical Membrane
Antigen1 (AMA1), MSP2 (Merozoite Surface Protein 2) and
MSP3 [3,4,5]. MSP2 is a ,28 kDa protein that is anchored in the
membrane of the merozoite by a C-terminal glycosylphosphatidyl-
inositol (GPI) anchor [6,7]. The function of MSP2 is unknown but
it appears to be essential for parasite viability, as attempts to
‘‘knock-out’’ the gene have not been successful [8,9].
Like many abundantly expressed surface proteins of the malaria
parasite, MSP2 is highly polymorphic. Polymorphisms are largely
confined to the central variable region of the protein, which is
flanked by a short N-terminal, and a longer C-terminal conserved
region [10,11]. The variable region consists of highly polymorphic
tandem sequence repeats and flanking non-repetitive dimorphic
sequences, which define the two allelic families of MSP2, 3D7 and
FC27, respectively. As it is abundantly expressed on the merozoite
surface [12], MSP2 is a potential target of antibodies induced by
infection or vaccination. The majority of individuals living in
regions where there is intense transmission of P. falciparum develop
high titres of anti-MSP2 antibodies in response to repeated
infections [13]. Much of the natural anti-MSP2 antibody response
is directed against epitopes in the central variable region of the
molecule as well as the dimorphic regions [14]. Several sero-
epidemiological studies, but not all [15], have shown an
association between antibody responses to MSP2 and resistance
to infection or disease [16,17,18,19]. MSP2-specific antibodies in
immune individuals are predominantly of the cytophilic IgG3
subclass [14,17,18,20].
Evidence that MSP2 has potential as a component of a malaria
vaccine came from the testing of the Combination B vaccine in
Papua New Guinea. This vaccine contained three recombinant
malaria proteins, all expressed in E. coli: full-length 3D7 MSP2, a
small N-terminal fragment of MSP1, and a large C-terminal
fragment of the ring-infected erythrocyte surface antigen. This
three component vaccine was adjuvanted with MontanideH ISA
720 (ISA 720) [21,22,23]. The development of Combination B
culminated in a Phase 1/2b double-blind randomized placebo-
controlled trial in 120 children 5–9 years of age living in the
Wosera region of the East Sepik Province of Papua New Guinea
[23]. One half of the subjects in this trial (60 individuals) were
drug-treated to eliminate existing parasitemias before vaccination.
The incidence of malaria parasitemia in these drug-treated
individuals was very low, a factor that impeded assessment of
vaccine efficacy in this group. In contrast, a significant reduction in
parasitemia was observed among the 30 vaccinated individuals
who were not drug-treated, with mean parasitemia reduced by
62% (p=0.024). Analysis of the msp2 genotypes in breakthrough
parasite populations demonstrated that among vaccinees in both
the drug-treated and untreated groups, there was a lower
prevalence of infection with parasites carrying the 3D7 allelic
form of MSP2 (corresponding to that in the vaccine). Furthermore,
over the 12-month follow-up, there was a higher incidence of
morbidity associated with P. falciparum infections of the FC27 msp2
genotype in the vaccine group [23]. This indicated that activity of
the Combination B vaccine was at least partially attributable to the
MSP2 component of the vaccine. Furthermore, the results
suggested that the vaccine may exert a selective pressure on the
parasite population by inducing immune responses that are more
active against parasites expressing forms of MSP2 belonging to the
3D7 dimorphic family than against parasites expressing forms of
MSP2 belonging to the FC27 dimorphic family. This finding
indicated that any further testing of a MSP2 vaccine should
include antigens representative of both families of MSP2 alleles,
which have been found in all infected populations examined [24].
Therefore we undertook a dose-escalating, double-blinded,
placebo-controlled Phase 1 trial in healthy, malaria-naı ¨ve adults of
a new MSP2 vaccine (MSP2-C1) containing the 3D7 and FC27
forms of MSP2, representative of the two families of MSP2 alleles.
Equal amounts of the two antigens were formulated in a water-in-
oil emulsion with ISA 720. Placebo subjects received saline
emulsified in ISA 720. The aims of the study were to test safety
and immunogenicity of this new vaccine.
Materials and Methods
Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist (Checklist S1)
and Protocol (Protocol S1)with Amendments (ProtocolS2, Protocol
S3 and Protocol S4). The study was approved by the Queensland
Institute of Medical Research Human Research Ethics Committee
(QIMR-HREC) and by the Western Institutional Review Board,
which is the designated research ethics board for PATH MVI, the
sponsor of the trial. The study was conducted in accordance with
the Declaration of Helsinki principles for the conduct of clinical
trials and the International Committee of Harmonization Good
Clinical Practice Guidelines as recognized by the Australian
Therapeutic Goods Administration (TGA; (www.tga.gov.au/
docs/pdf/euguide/ich/ich13595.pdf). The trial was conducted
with Regulatory oversight by the TGA under the CTN scheme,
and registered at the Australian and New Zealand Clinical Trials
registry (www.anzctr.org.au/ACTRN12607000552482.aspx).
Vaccine preparation
The two antigens in MSP2-C1 were manufactured at GroPep
Pty Ltd (Adelaide, Australia). Briefly, both 3D7 and FC27 MSP2
were expressed in E. coli from synthetic genes cloned into the E. coli
expression plasmid pET22b (GenBank Accession numbers:
JN248383 and JN248384 respectively). Each recombinant protein
had a 6-histidine C-terminal tag to allow purification by metal-
chelate chromatography. The two recombinant proteins
(EcMSP2-3D7 and EcMSP2-FC27) were purified from E. coli
lysates by a combination of chelating, anion-exchange and reverse-
phase chromatography. The purification processes were designed
to separate monomeric MSP2 from non-product related compo-
nents (e.g. E. coli proteins, DNA and endotoxin), as well as MSP2
aggregates or fragments. Both recombinant forms of MSP2 have a
propensity to form amyloid-like fibrils [25] but this was inhibited
by storing the purified antigens at -80uC in 10 mM acetic acid.
EcMSP2-3D7 and EcMSP2-FC27 were shown by analytical
reverse-phase chromatography to be .95% and .93% monomer,
respectively. On SDS-PAGE a single species was detected in each
of the protein preparations but the electrophoretic mobility of
EcMSP2-3D7 and EcMSP2-FC27 differed slightly, thus allowing
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formulated vaccine. Equal amounts of the two antigens were
formulated in the experimental adjuvant ISA 720 (SEPPIC Inc) at
CSL Ltd (Melbourne, Australia). A water-in-oil emulsion, with a
droplet size of ,1 micron, was generated by homogenization.
Glycine (final concentration 250 mM) was added to the aqueous
phase prior to homogenization because this has been shown to
minimise modifications that can occur in ISA 720 emulsions [26].
The individual antigens stored at 280uC and the antigens in the
formulated vaccine, stored at 4uC were shown to be stable for 24
and 18 months, respectively.
Study design
The study was designed as a dose-escalating, placebo-controlled
Phase 1a trial to assess the safety and immunogenicity of three
dosages of MSP2-C1/ISA720. The study was planned to include
45 volunteers to be vaccinated in three cohorts of 15 (10, 40, or
80 mg of MSP2-C1 formulated in ISA 720); volunteers in each
cohort were randomized to receive vaccine (n=12) or ISA 720
emulsion as a control (n=3), with a dosing interval of 12 weeks
planned between each immunization. The three cohorts were
screened and enrolled consecutively. For cohorts two and three, it
was planned that immunizations be staggered, such that the first
five volunteers of both cohorts be vaccinated four weeks before the
remaining 10. All study staff including the volunteers, investiga-
tors, individuals responsible for the evaluation of study subjects
and laboratory personnel were blinded to the randomization
scheme except for the study pharmacist (or designee) who
prepared the vaccine dose for administration. The volumes of
vaccine and ISA 720 Control were identical for each group. Code-
break envelopes for individual participants were provided to
account for the contingency that the Investigator needed to break
the code for an individual subject.
Participants
A total of 45 healthy, malaria naı ¨ve male and female
volunteers, aged between 18 and 45 years were recruited from
a database of healthy volunteers maintained by Q-Pharm, or by
advertisement to students of The University of Queensland or to
the general community. A screening medical history, a physical
examination, and laboratory testing were performed after written
informed consent was obtained. Details of the inclusion and
exclusion criteria are available in the Protocol in the supplemen-
tal material.
Assessment of safety
Volunteers were observed for at least 30 minutes after each
vaccination, contacted by phone on day 1 and evaluated at the
study site on days 3, 7 and 14 after every immunization. At each
visit, the volunteers underwent an abbreviated history and physical
examination, including examination of injection site, emphasising
examination of any acute complaints. Local reactions at the
injection site were evaluated according to Brighton collaboration
definitions, (www.brightoncollaboration.org). Safety was also
assessed by serial laboratory evaluations of clinical chemistry and
hematology on blood samples collected on days 3, 14 and 56 days
after immunization. After the detection of creatine phosphokinase
elevations (CPK) in two volunteers following the first dose of 40 mg
MSP1-C1, a specific history indicating symptoms of muscle
damage (exercise history, symptoms of myositis) was solicited in
volunteers. Progress of the trial and review of its safe conduct was
overseen by a safety monitoring committee, comprising three
independent medical experts.
Assessment of Immunogenicity
For evaluation of immunogenicity, blood samples were collected
on Day 0 prior to receipt of the first vaccination, one month after
each immunization, and at the end of study on Day 360 for
assessment of antibody responses by ELISA, immunofluorescence
assays (IFA) with fixed P. falciparum schizonts, in vitro growth
inhibition assays (GIA), Western blotting of parasite protein
extracts, and antibody-dependant cellular inhibition assay (ADCI).
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinised blood samples, washed in PBS and immediately used
for lymphocyte stimulation assays.
ELISAs were performed using established methods [27,28]. 96-
well plates (Maxisorp, Nunc, Roskilde, Denmark) were coated with
recombinant proteins at 1 mg/ml in PBS overnight at 4uC. Plates
were washed and blocked with 0.1% casein in PBS with 0.05%
Tween 20 (PBS-T) for 2 hours. After washing, serum samples
(100 ml/well in duplicate), diluted in PBS-T plus 0.1% casein, were
incubated for two hours. Plates were washed and incubated for
one hour with HRP-conjugated anti-human IgG at 1/5000
(Chemicon, Melbourne, Australia) in PBS-T plus 0.1% casein.
After washing, colour was developed by adding azino-bis(3-
ethylbenthiazoline-6-sulfonic acid) liquid substrate system (Sigma-
Aldrich, Sydney; stopped with 1% SDS after 15 mins) and the
absorbance was read by spectrophotometry. All washes were
performed with PBS-T, and all incubations were at room
temperature. Positive and negative controls were included on all
plates to enable standardisation. Serum samples were tested at 1/
100 and 1/500 dilution; only results from testing at the 1/100
dilution are reported as no major differences in the pattern of
reactivity were found when testing samples at 1/500. All available
serum samples were tested for IgG responses to recombinant 3D7
and FC27 MSP2, the two vaccine antigens. Samples tested were:
Cohort 1 – Day 0, 28, 84, 112, 168, 196, and 336; Cohort 2 – Day
0, 28, 84, 112, 168, 336 (note that day 196 was not available for
this cohort). All samples were randomized and coded for testing in
a blinded manner.
For Western blot and immunofluorecent antibody assays (IFA)
schizont-stage isolates of the P. falciparum strains 3D7 and D10 [a
clone of the FC27 parasite line] were prepared from parasites
cultured in RPMI-HEPES with 0.5% Albumax [4]. A subset of
samples (n=3) for testing in western blots and IFAs were selected
on the basis that they were highly reactive by ELISA (in the top
half of responses) at day 112. For IFA, parasites were washed and
smeared onto glass slides and fixed with methanol/acetone (10:90,
v:v). Smears were blocked with 0.1% casein in PBS, incubated
with cohort samples (diluted 1:1000), then Alexa-Fluor 488-
conjugated anti-human IgG. Slides were cover-slipped and
examined by fluorescence and light microscopy. For Western
blots, parasite proteins were extracted into 1% Triton X100
(TX100) in PBS with protease inhibitors (Roche), separated by
SDS-PAGE and transferred onto PVDF membranes. Membranes
were blocked with 0.1% casein in PBS, incubated with cohort
samples diluted 1/500 in PBS with 0.1% casein, and then with
HRP-conjugated anti-human IgG. IgG-binding was determined
by chemiluminescence.
PBMC for lymphocyte stimulation assays were prepared in
Hepes-buffered RPMI-1640 with, 100 IU/mL Penicillin-Strepto-
mycin (GIBCO BRL, Invitrogen), and heat-inactivated autologous
serum in 96 well flat-bottomed plates in a volume of 200 ml/well.
Positive control cultures were established with 10% serum and the
mitogen phytohaemagglutinin (PHA; 2.2 mg/ml). Antigen-specific
cultures were established with heat-inactivated autologous serum
at a concentration of 20% and each antigen individually at 1 and
10 mg/ml. Plates were incubated (six days, 37uC, humidified 5%
Phase 1 MSP2-C1 Vaccine Trial
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3H thymidine, 40 mCi/ml, 16–
18 hours) and harvested onto filter mats using a PerkinElmer
FilterMate harvester. Incorporated
3H-thymidine was determined
using a PerkinElmer MicroBeta TriLux 1450 LSC Luminescence
counter. Stimulation indices (SI) were calculated relative to control
wells to which no recombinant antigen had been added. For
inclusion of data, replicate values of thymidine incorporation were
required to be within 150% of each other, and replicate
unstimulated and mitogen-stimulated values to be consistent.
Two growth inhibition assays (GIAs) were used to assess the
ability of induced anti-MSP2 antibodies to inhibit parasite
replication in vitro. In one assay serum samples from day 0 and
day 112 were tested in a two-cycle flow cytometry-based assay
[27,29] for all subjects at 1/10 and 1/5 dilution against 3D7 and
D10 (FC27) parasites. Randomized and coded serum samples
were filter sterilized before testing. The P. falciparum lines 3D7 and
D10 were cultured in vitro [4] and synchronised by alternate day
re-suspension in 5% D-sorbitol (Sigma, St Louis, MO, USA) in
water. Growth assays were performed over two cycles of parasite
replication and parasitemias were measured using flow cytometry
(FacsCalibur, Becton, Dickinson, Franklin Lakes, NJ). Assays were
set-up with mature trophozoites and schizonts, at 1% hematocrit
and 0.3% starting parasitemia (50 ml/well) in 96 well U-bottom
culture plates (Becton Dickinson, Franklin Lakes, USA) with
serum samples from cohort members. On all plates, PBS and
samples from non-exposed Australian residents were included as a
non-inhibitory controls and 1F9 anti-AMA1 monoclonal antibody
[30] was included as an inhibitory control. Parasite growth for
each sample is expressed relative to plate PBS controls. All samples
were tested in duplicate in two separate assays.
GIA was also assessed using IgG fractions isolated from serum
samples collected from 10 subjects on days 0 and 112.; all subjects
were positive for antibodies to MSP2 by ELISA on day 112. IgG
from serum samples was purified using protein G-Sepharose
columns, dialysed, and then concentrated to 20 mg/ml. IgG
samples, at a final concentration of 10 mg/mL, were incubated
with the 3D7 P. falciparum blood-stage parasites for ,40 hours.
Parasite growth was then determined by colorimetric quantifica-
tion of P. falciparum lactate dehydrogenase, [31].
The effect of purified IgG on parasite growth, measured by
antibody-dependant cellular inhibition (ADCI) was performed as
described previously [32]. IgG samples purified from the day 0
and day 112 of 10 subjects (as described above) were tested at a
final concentration of 1 mg/ml for ADCI activity against the 3D7
and K1 parasite lines, expressing the 3D7 and FC27 msp2 alleles,
respectively. Isolates were obtained from MR4 and identity was
confirmed by genotyping. Potential contamination of cultures with
Mycoplasma was excluded by PCR testing. PBMC from healthy
and malaria naı ¨ve blood donors were separated by Ficoll-Hypaque
and then aliquoted at a final concentration of 25610
6 cells/ml in
cryopreservation medium and stored in liquid phase of liquid
nitrogen. Aliquots were kept in liquid nitrogen until use.
Identification and enumeration of the monocyte sub-population
was assessed by flow cytometry using anti-CD14-PE (mAb clone
RMO2, a murine IgG2a, that emits a yellow colour at 575 nm),
and anti-CD16-PC5 (mAb clone 3G8, a murine IgG1 that emits in
dark red-brownish at 670 nm); both from Beckman Coulter. A
single batch of monocytes was used for all experiments performed.
Assays were performed in 96-well culture plates containing 2610
5
monocytes per well with 100 ml of an asynchronous culture of
either 3D7 or K1 P. falciparum-infected red blood cells at 0.5%
parasitemia and 2.5% hematocrit. Cultures were incubated for
72 hours and the number of infected erythrocytes per well was
determined by flow cytometry using double-staining with hydro-
ethidine and thiazole orange dyes [33]. IgG purified from African
adults from Ivory Coast employed previously to passively transfer
protection, and IgG purified from non-exposed donors were used
as positive and negative controls respectively. Specific growth
inhibition (SGI) was calculated as SGI=1006[1-(percent parasit-
emia with MN and test sample/percent parasitemia with test
sample)/(percent parasitemia with MN and control IgG/percent
parasitemia with control IgG)]. As previously described, the
threshold of positivity in this assay is $30% SGI. To take into
account experimental variations results are reported as Adjusted-
SGI relative to the positive reference control employed in each
ADCI plate.
Statistical methods
Sample Size. A group size of 12 volunteers per dose, with 9
participants receiving the MSP2-C1/ISA720 malaria vaccine and
3 per dose cohort receiving ISA 720 Control vaccine was selected,
as it was powered to provide sufficient safety data on an adult
population living in an area without malaria. It was calculated to
have a power of 80% for detecting one or more serious or severe
adverse events that occurred with a probability of 0.15 per
volunteer.
Statistical Analysis. The incidence of adverse events (AEs)
and serious adverse events (SAEs) were tabulated by dose and
treatment group, with the pooled ISA 720 Control patients
representing one group. It was planned to compare the incidence
in each treatment group with that in the pooled ISA 720 Control
group using Fisher’s exact test (correcting for multiple comparisons
across AEs using Holm’s method [34]). The overall number and
percentage of volunteers with at least one AE and SAE were
tabulated after each vaccination and over the entire study period.
The incidence, intensity, and relatedness to vaccination of
individual symptoms were calculated for each dose and study
arm. The incidence, intensity and relatedness to vaccination were
calculated for each treatment group. Safety analyses were based on
intention to treat data selection.
Antibody levels between study groups at each time point were
compared using Mann-Whitney U tests. Wilcoxon signed rank
sum tests were used to compare the difference in antibody levels
and ADCI activity between day 0 and other time points. The
correlation between MSP-2-3D7 and MSP-2-FC27 responses at
day 112 was assessed using Spearmans rho. One subject (subject 4)
withdrew after the baseline bleed and was thus excluded from
analysis. All other data points were used in the analysis. All p
values,0.1 are shown. Analysis was performed using GraphPad
Prism, and SPSS software packages.
Results
Participants
Participants were recruited at the trial site, Q-Pharm Pty Ltd,
Brisbane, QLD, Australia from November 2007 until February
2008. Of 41 potential study subjects screened for enrolment in
cohorts one and two, 30 were deemed eligible and enrolled
(Figure 1). Reasons for exclusion included declining to consent
(n=6), possible past malaria exposure (n=1), and incompatible
chronic medications (n=1). Table 1 shows the demographics of
volunteers per randomised group. The mean age was 26 (range
19–37 years); 25 of 30 subjects were of Caucasian background.
Participant flow
Ten of 15 subjects in cohort 1 received all three immunizations.
Five subjects, all in the vaccine arm of cohort 1 did not receive all
three doses of vaccine (Figure 1, Table 2). Four of these five were
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included loss to follow-up (n=1; after first immunization); bilateral
ear lobe dermatitis suspected to be due to Nickel allergy (n=1;
after second immunization); appendectomy (n=1; after second
immunization); received Human Papilloma Virus immunization in
the interval between screening and enrolment (n=1). The fifth
volunteer was withdrawn from the study after developing a sterile
abscess after the second dose of vaccine (see below).
Eleven of the 15 enrolled subjects in cohort 2 received two
immunizations. Four volunteers received one immunization, 3 for
reasons judged not to be related to vaccination (n=1: discovery of
pre-existing hepatic condition, the ISA 720 control group; n=2:
significant, exercise-related transient CPK elevation, one subject in
each treatment arm). One subject in the vaccine arm of cohort 2
was withdrawn from receipt of further doses of vaccine after
developing a Grade 3 local reaction (see below) but was followed
for safety for the duration of the study. The investigators, in
consultation with the Safety Monitoring Committee decided not to
proceed with immunizing Cohort 3 subjects due to two observed
severe local reactions that had occurred in Cohort 1 and 2
subjects. Due to a failed in vivo potency test of the stored
formulated vaccine at 13 months, Cohort 2 subjects did not
receive their third scheduled immunization.
Safety and reactogenicity
No serious adverse events occurred that were definitely, probably,
or possibly related to immunization. As noted above, one subject
(cohort 2, ISA 720 control) was discovered to have pre-existing
fluctuating derangements in liver function tests. A further two
volunteers (1 subject in each arm of cohort 2) were found to have
transient elevations in ALT and AST levels, as well as significantly
elevated CPK levels. These were attributed in both cases to vigorous
Figure 1. Participant Flow.
doi:10.1371/journal.pone.0024413.g001
Table 1. Study subjects.
Cohort 1
MSP2 10 mg+ISA 720
(n=12)
Cohort 2
MSP2 40 mg+ISA 720
(n=12)
Pooled Control ISA 720
(n=6)
Race Caucasian 11 10 4
Asian 1 0 1
South Asian 0 1 1
Latin American 0 1 0
Age Mean (SD) 24.2 (6.6) 28.1 (7.1) 25.7 (5.3)
Range 18–39 19–39 20–33
Sex Male/Female 4/8 4/8 4/2
doi:10.1371/journal.pone.0024413.t001
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preceding the blood collections. No other clinically relevant changes
in vital signs or laboratory values were reported throughout the study.
Volunteers in both Cohort 1 and Cohort 2 experienced local
injection site reactions. The most commonly reported reaction was
injection site pain, with 29 of 30 subjects reporting at least transient
mild to moderate pain (Table 3). These reactions were sufficiently
severe to require the withdrawal of two volunteers from further
vaccination. No relationship was discernable between the likelihood
of local reaction and the dose of vaccine administered or whether it
was the first or subsequent immunization. One subject in the 10 mg
vaccine cohort developed an abscess measuring 362 cm 3 days after
the second immunization, and one subject in the 40 mg vaccine group
developed grade 3 pain, swelling and erythema, accompanied by
moderate induration beginning on the day of the first immunization.
Humoral immune response
Immunization induced significant IgG responses to the FC27
and 3D7 isoforms of MSP2 in both cohorts 1 and 2 (Figure 2;
Table 2. Subjects not completing study procedures.
Group Vaccine doses received Reason
MSP2 10 mg+ISA 720 1 Lost to Follow-up
1 Jewellery allergy (Concern re Nickel allergy)
1 Protocol violation
2 Appendicitis
2 Sterile abscess at injection site
MSP2 40 mg+ISA 720 1 Grade 3 Local AE after vaccination
1 Withdrawn from further vaccination because of exercise-induced CPK elevation
Pooled Control ISA 720 1 Pre-existing fluctuating LFT abnormality discovered
1 Withdrawn from further vaccination because of exercise-induced CPK elevation
doi:10.1371/journal.pone.0024413.t002
Table 3. Local Reactions.
Cohort 1
MSP2 10 mg+ISA 720
(n=12)
Cohort 2
MSP2 40 mg+ISA 720
(n=12)
Control
ISA 720 10 mg
(n=3)
Control
ISA 720 40 mg
(n=3) Total
Pain
Mild 12 7 2 2 23
Moderate 0 4 1 0 5
Severe 0 1
{{ 001
Swelling
Mild 3 1 0 0 4
Moderate 1 2 1 0 4
Severe 0 1
{{ 001
Erythema
Mild 0 0 1 0 1
Moderate 0 2 0 0 2
Severe 1 1
{{ 002
Induration
Mild 1 1 2
Moderate 2 2
Severe
Nodule
Mild 1 1
Moderate
Severe
Sterile Abscess 1
{
{362 cm abscess beginning three days after second immunization; subject withdrawn from further doses of vaccine; abscess resolved spontaneously.
{{Subject developed severe pain, swelling and erythema, accompanied by moderate induration beginning on the day of the first immunization; subject withdrawn from
further doses of vaccine; adverse events resolved spontaneously.
doi:10.1371/journal.pone.0024413.t003
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from both cohorts 1 and 2 had higher antibody levels against 3D7
MSP2 (P=0.062 and P=0.008 in cohorts 1 and 2, respectively)
and FC27 MSP2 (P=0.004 and P=0.003, respectively) compared
to day 0. At day 112 (3 months after day 0, and 1 month after dose
2) antibody responses peaked and were significantly higher
compared to day 0 for both antigens (P#0.003). After day 112,
antibody responses waned; although responses were higher at day
Figure 2. Antibodies to MSP2 recombinant proteins were induced by immunization. Serum IgG binding to recombinant MSP2
representing the 3D7 (A) and FC27 (B) alleles was measured by ELISA at all available time points from cohort 1 and cohort 2, comparing those who
received active vaccine versus placebo. Results show the median at each time point; placebos from cohort 1 and 2 were combined. P,0.01
comparing day 0 versus day 112 IgG levels for cohort 1 and 2, and for 3D7 and FC27 (excluding placebo recipients); p,0.01 comparing placebo
versus active vaccine recipients at day 112 for 3D7 and FC27. Immunizations were given at day 0, day 84, and day 168 for cohort 1 (20 ug/dose), and
day 0 and day 84 for cohort 2 (40 mg/dose).
doi:10.1371/journal.pone.0024413.g002
Table 4. IgG responses for MSP2-3D7 and MSP2-FC27 according to study day and cohort.
Day 0 Day 28 Day 84 Day 112 Day 168 Day 196 Day 336
Antibody
and dilution
Median (range)
No. Positive (%)a
Median (range)
No. Positive (%)a
Median (range)
No. Positive (%)a
Median (range)
No. Positive (%)a
Median (range)
No. Positive (%)a
Median (range)
No. Positive (%)a
Median (range)
No. Positive (%)a
MSP-2-3D7 IgG
Cohort 1 0.080 (0.033–0.203) 0.125 (0.030–0.732) 0.138 (0.035–0.504) 0.757
(0.123–1.490)**
0.548
(0.068–1.368)*
0.539 (0.071–1.277) 0.156 (0.048–0.771)
2/11 (18.2) 4/11 (36.4) 5/11 (45.5) 9/11 (81.8) 8/11 (72.7) 8/11 (72.7) 5/11 (45.5)
Cohort 2 0.111 (0.044–0.402) 0.232
(0.087–0.641){
0.289 (0.072–0.772)* 1.360
(0.129–1.649)***
0.974
(0.116–1.544)***
. 0.298
(0.123–1.169)*
1/12 (8.3) 8/12 (66.7) 9/12 (75) 11/12 (91.7) 11/12 (91.7) . 11/12 (91.7)
Placebo 0.081 (0.067–0.483) 0.098 (0.059–0.700) 0.081 (0.048–0.495) 0.110 (0.033–0.542) 0.098 (0.040–0.517) 0.12 (0.052–0.529) 0.105 (0.046–0.550)
1/6 (16.7) 1/6 (16.7) 1/6 (16.7) 1/6 (16.7) 1/6 (16.7) 4/6 (66.7) 1/6 (16.7)
MSP-2-Fc27 IgG
Cohort 1 0.028
(0.021–0.094)**
0.082 (0.031–0.567){ 0.110 (0.036–0.460) 0.915
(0.146–1.319)**
0.467
(0.067–1.298)*
0.397
(0.057–1.176)*
0.189
(0.035–0.767)
1/11 (9.1) 4/11 (36.4) 8/11 (72.7) 11/11 (100) 10/11 (90.9) 10/11 (90.9) 8/11 (72.7)
Cohort 2 0.043
(0.027–0.219)
0.264
(0.041–0.469)
0.323
(0.059–0.718)*
1.132
(0.086–1.552)***
0.785
(0.067–1.363)**
. 0.287
(0.084–1.146){
3/12 (25) 10/12 (83.3) 10/12 (83.3) 11/12 (91.7) 11/12 (91.7) . 11/12 (91.7)
Placebo 0.076 (0.049–0.266) 0.081 (0.051–0.292) 0.071 (0.043–0.282) 0.069 (0.047–0.322) 0.066 (0.045–0.265) 0.087 (0.072–0.101) 0.071 (0.067–0.238)
2/6 (33.3) 2/6 (33.3) 1/6 (16.7) 2/6 (33.3) 1/6 (16.7) 4/6 (66.7) 1/6 (16.7)
aPositives were defined as those with an OD greater than median +3 median absolute deviations calculated from antibody data from Day 0 bleeds (all groups
combined).
{P,0.1,
*P,0.05,
**P,0.01,
***P#0.001.
P-values represent comparisons of Cohort 1 and Cohort 2 with Placebo group as assessed using Mann-Whitney U test.
doi:10.1371/journal.pone.0024413.t004
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comparable to day 28 levels (P.0.11). Only subjects in Cohort 1
received a third dose of vaccine at day 168 and interestingly, one
month after this third dose (day 196) there was limited increase in
IgG to both 3D7 and FC27 MSP2 (P=0.11 and P=0.075,
respectively, Figure 2; Table 4), and responses were lower than
those seen at day 112 (P#0.021). Antibodies at day 112 to 3D7
and FC27 MSP2 were highly correlated (r=0.934, P,0.001).
As anticipated, IgG levels to both 3D7 and FC27 MSP2 were
significantly higher in the acti v et h a ni nt h ep l a c e b og r o u p
(P#0.003) at day 112. Although total IgG responses waned after
day 112, there was still evidence of higher antibody levels in the
active group at day 196 and day 336 (Table 4). Median 3D7
MSP2 IgG levels were consistently higher in cohort 2 compared
to cohort 1 at all time points (Figure 2; Table 4), although this
did not reach statistical significance except at day 168 for which
there was some evidence of increased 3D7 MSP2 responses in
cohort 2 compared to cohort 1 (P=0.045). For FC27 MSP2,
levels of IgG were generally higher in cohort 2 compared to
cohort 1 at day 28 (P=0.049), day 84 (P=0.036), day 112
(P=0.14) and day 168 (P=0.045) (median [range] values shown
in Table 4).
Recognition of native MSP2 by serum antibodies
Selected samples collected at day 112 that had high IgG
reactivity to recombinant proteins by ELISA were tested for
antibody reactivity with native proteins. In Western blots, ELISA-
positive day 112 samples clearly labelled bands corresponding to
MSP2 in schizont protein extracts from 3D7 and D10 parasites
(Figure 3A). There was no reactivity observed with day 0 samples
collected from the same individuals. ELISA-positive day 112
samples also labelled merozoites by indirect immunfluorescence
assays using fixed smears of schizont-stage parasites of 3D7 and
D10 lines (Figure 3B). There was no labelling of merozoites by day
0 samples collected from the same individuals.
Antibody inhibition of P. falciparum growth in vitro
GIA. There was no evidence of GIA activity induced by
immunization with the active vaccine when samples were tested at
1/10 and 1/5 dilutions using a FACS-based two-cycle assay
(Figure 4). No significant differences were seen when comparing
day 112 versus day 0, active vaccine versus placebo at day 112, or
cohort 1 versus cohort 2 at day 112. The range of inhibitory
activity was very similar for day 0 versus day 112 samples, and for
active vaccine versus placebo among day 112 samples. In addition,
purified IgG from day 0 and day 112 samples collected from 10
subjects was tested at a final concentration of 10 mg/ml in a one-
cycle assay using pLDH activity to measure parasite growth.
Again, there was no evidence of GIA activity against 3D7 parasites
comparing active vaccine versus placebo (data not shown), even
though all day 112 samples were positive for antibodies to MSP2
by ELISA.
ADCI. Purified IgG was prepared from day 0 and day 112
serum samples from 10 individuals who had the highest MSP2 IgG
levels by ELISA post-immunization (5 subjects each from cohort 1
and 2). These blinded pre and post immunization samples were
tested for ADCI activity against 3D7 and K1 parasites,
representing the 3D7 and FC27 MSP2 allelic families,
respectively. ADCI activity was significantly higher among day
112 samples compared to day 0 for both the 3D7 and K1 parasite
lines (P=0.012 and P=0.006, respectively; Figure 5). For 3D7
parasites, median adjusted inhibition was 29.5% for day 0 versus
79.0% for day 112. For K1 parasites, median adjusted inhibition
was 34.0% for day 0 versus 83.0% for day 112. There was a strong
correlation between ADCI activity for 3D7 versus K1 parasites
(r=0.926; P,0.001). Of note, two day 0 samples had substantial
ADCI activity (70% and 76% for 3D7; 62% and 81% for K1), and
two day 112 samples had relatively low activity (27% and 42% for
3D7; 28% and 36% for K1). In exploratory assays these four
samples were retested in a blinded manner against 3D7, with the
results suggesting that a laboratory error had resulted in an
Figure 3. Labelling of native proteins of P. falciparum strains 3D7 and D10 (a clone of FC27) by Western blot (A) and
immunofluorescence microscopy (B). A. Serum antibodies from a representative subject collected at day 112 post-immunization bound to MSP2
present in schizont protein extracts. Serum antibodies from the same subject collected at baseline (day 0) did not react with parasite proteins. B.
Serum antibodies from a representative subject collected at day 112 post-immunization labelled merozoites.
doi:10.1371/journal.pone.0024413.g003
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Supplementary Information Table S1).
Cellular immune response
Interpretation of assays of proliferation of freshly collected and
isolated PBMC was hampered by technical problems that resulted
in poor agreement between replicate samples, both in control wells
containing unstimulated cells and in wells containing vaccine
antigen. Nevertheless, the overall data suggested that there was a
cellular immune response to 3D7 and FC27 antigens induced in a
proportion of volunteers (Supplemental material, Figure S1);
stimulation indices at some post-vaccination time points were
significantly higher than day 0.
Discussion
This is the first clinical trial of a malaria vaccine containing two
isoforms of MSP2 that represent the two families of msp2 alleles in
P. falciparum. Although the vaccine was immunogenic, unaccept-
able, frequent and occasionally severe injection site adverse events
were observed in subjects in the two lower dose cohorts. Because
of this unacceptable reactogenicity, a decision was made in
consultation with the Safety Monitoring Committee not to
proceed with vaccination of subjects in the third and highest dose
cohort. Further clinical evaluation of MSP2-C1 will therefore
require that it be formulated with an alternative adjuvant.
MSP2-C1 formulated in ISA 720 induced significant antibody
responses to both forms of MSP2 in the majority of subjects
receiving the vaccine, and an increased antigen dose resulted in
higher antibody responses. Furthermore, antibodies induced by
immunization recognized native MSP2 by Western blot of parasite
protein extracts and IFA of whole parasites. When the potential
functional activity of the induced anti-MSP2 antibodies was
evaluated, no in vitro GIA was observed. However, significant
ADCI activity against parasites of both MSP2 types was seen,
indicating potentially important functional activity of the vaccine-
induced antibodies. These findings provide further support for
MSP2 as a blood stage vaccine candidate. This is in addition to
sero-epidemiologic evidence for a role for MSP2 in acquired
immunity [16,17,18,19], and evidence of protective efficacy of the
Phase 2 trial of the MSP2-containing vaccine, Combination B
[23].
Although some anti-MSP2 antibodies have been reported to
have direct in vitro growth-inhibitory activity [35,36], and there is
indirect evidence that naturally occurring antibodies to MSP2
inhibit merozoite invasion [37], our results are consistent with
other studies that have shown that naturally-acquired antibodies to
MSP2 mediate ADCI but lack growth-inhibitory activity [38]. The
reasons for the lack of direct inhibitory activity of human MSP2
antibodies are unclear, as MSP2 is assumed to have an essential
role in the attachment and invasion process. Possibly, the
antibodies induced by immunizing with recombinant MSP2 do
Figure 4. Immunization with MSP2 did not induce growth-inhibitory antibodies. Serum samples collected from all subjects at day 0 and
day 112 post-immunization were tested in growth-inhibition assays over 2 cycles of erythrocyte invasion using 3D7 (A, B) and FC27 (C, D) parasites.
There was no significant difference in parasite growth in the presence of samples comparing day 0 versus day 112 (A, C; placebo recipients excluded)
or active vaccine versus placebo (B, C; day 112 samples only). The median (6interquartile range) is indicated by a horizontal bar.
doi:10.1371/journal.pone.0024413.g004
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inhibit invasion directly.
The functional antibody assays were performed on day 112
samples, which coincided with the peak antibody response, four
weeks after the second immunization. The antibody responses
decayed markedly beyond day 112. Among subjects in cohort 1
who received a third immunization at day 196, only a slight boost
in the response was observed. In view of the changes in antibody
responses over the course of the trial, it is interesting to note that in
the PNG Phase 2b study with Combination B, partial protection of
the children was achieved by giving only two immunizations four
weeks apart with the ISA 720-formulated vaccine. It is important
to note that the limited number of participants who received the
intended vaccine schedule, limits the interpretation of the antibody
responses induced in the study.
Although the GIA has been widely used to assess antibody
responses to asexual blood-stage vaccine candidates, evidence that
activity in this assay correlates with protective immunity, and is
predictive of vaccine efficacy is limited [29,39]. There is
accumulating evidence that cytophilic antibodies specific for
merozoite surface proteins, which are required for ADCI and
possibly other Fc receptor-mediated effector mechanisms, are
associated with clinical immunity [18,40,41] to this and other
malaria vaccine candidates [5]. In this study, ADCI activity was
seen across a range of volunteer IgG concentrations, an
observation in agreement with previous findings [38,42]. The
positive outcome of the ADCI experiments with both the 3D7 and
FC27 alleles of MSP2 is in keeping with the ELISA data showing
satisfactory antibody responses to both MSP2 alleles. Assessing the
role of these different effector mechanisms mediated by cytophilic
anti-MSP2 antibodies, and the development of standardized assays
for them, will be important for the further development of the
MSP2-C1 vaccine and other blood stage vaccine candidates.
In previous human trials of recombinant MSP2, only a single
(3D7) form of MSP2, known as Ag1624, was studied. Ag1624
differs from the 3D7 MSP2 used here in that the hexa-His tag was
located at the N-terminus rather than the C-terminus, and there
were a small number of additional amino acid residues, at both the
N- and C-termini of Ag1624, which were derived from the cloning
site in the expression plasmid. In the first trial of Ag1624 where it
was evaluated in combination with recombinant circumsporozoite
protein (CSP) formulated on alum [43], no serious adverse events,
and only mild injection site reactions were observed. However, the
immune response was suboptimal, and no protection was observed
when 5 subjects were experimentally challenged with P. falciparum
after a third immunization [22].
After immunogenicity studies in animals [44], ISA 720 was
chosen as the adjuvant to provide enhanced immune responses to
Ag1624 and the other components of the Combination B vaccine
(MSP1 and RESA). In two Phase 1 trials conducted in Australia in
1997 to test the safety and immunogenicity of the Combination B/
ISA 720 vaccine candidate in healthy Australian volunteers [21],
local reactions were common, particularly pain and tenderness on
use of the injected muscle beginning shortly after vaccination and
lasting a few days. In a smaller number of subjects (10 of 26 in the
second study), delayed pain and tenderness developed approxi-
mately 10 days after the initial injection. The secondary reactions
were mild to moderate in all but one of the subjects who developed
severe pain and swelling in the injected thigh 10 days after the
dose. When this subject was administered a second dose in the
other thigh, the initial local response was mild. However, six weeks
later a hard painful mass that limited mobility developed at the
second injection site. This resolved over a few weeks. In the
challenge trial referred to above [22], where the effect of the
Combination B/ISA720 vaccine on in vivo parasite growth rate
was tested in 12 subjects receiving active vaccine compared to five
control subjects who received ISA 720 alone, one of the 12
volunteers had pain and tenderness after the first vaccine dose that
was of sufficient severity to preclude a second injection.
Combination B was then assessed in two trials in Papua New
Guinea. The first study [45], undertaken in 10 healthy adult males
was to assess the safety and immunogenicity. Poor cellular immune
responses to MSP2 were observed, with no change in the anti-
MSP2 antibody titers from baseline values. Approximately half the
subjects had mild pain at the injection site. Subsequently, a Phase
1/2b double-blind randomized placebo-controlled trial was
carried out in 120 children 5–9 years of age living in a malaria
Figure 5. Immunization with MSP2 induced antibody-depen-
dent cellular inhibition activity against P. falciparum. IgG was
isolated from serum samples collected at day 0 and day 112 post-
immunization from 10 subjects and tested in for ADCI activity using 3D7
parasites or K1 parasites. Results are expressed as inhibition relative to
control (adjusted ADCI, %). The median is indicated by a horizontal bar.
There was a statistically significant difference in ADCI activity between
day 0 and day 112 samples for assays using 3D7 and K1 parasites
(p=0.0108 and p=0.0059, respectively; Wilcoxon matched pairs test).
All samples were positive for antibodies to recombinant MSP2 by ELISA
for day 112 samples; no samples from placebo recipients were included.
doi:10.1371/journal.pone.0024413.g005
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events occurred in children receiving vaccine or placebo. It was in
this study that the protective efficacy of the MSP2 component was
identified.
In addition to five trials of MSP2 where ISA 720 has been used
as the adjuvant, ISA 720 has been used in 10 Phase 1 studies
testing safety and immunogenicity of other malaria vaccine
candidates [47,48,49,50,51,52,53,54,55,56] and in three non-
malaria Phase 1 clinical trials [57,58,59]. As has been observed in
the MSP2 trials, formulations of other malaria vaccines with ISA
720 have in general been more reactogenic than those formulated
with Alum, with the most common adverse events being local
reactogenicity at the injection site. While local reactions were more
common in trials where the vaccine was given subcutaneously
[48,52] than when given by the intramuscular route, sterile abscess
and moderate to severe local reactions have been reported in
studies where ISA 720-formulated vaccines have been adminis-
tered intramuscularly. It has been suggested that the rather
unusual pattern of delayed local reaction that has been reported in
volunteers administered ISA 720-formulated vaccines is caused by
Arthus-type reactions (type III hypersensitivity) induced by
antibodies to the vaccine antigen [51]. However, it has not been
possible to confirm this by histological analysis as no biopsies have
been taken.
The three non-malaria phase 1 clinical trials where ISA 720 has
been used as an adjuvant include a trial of an experimental HIV-1
vaccine [57], a peptide vaccine against Epstein Barr virus (EBV)
infection [58], and a melanoma vaccine [59]. The HIV vaccine
was highly immunogenic but the reactogenicity in many subjects
was severe, with pain & tenderness, induration, erythema,
granuloma and sterile abscess formation reported to be mild to
severe. The severity of the local reactions was related to antigen
dose, the highest dose (1 mg) being much higher than in any other
clinical trial of an antigen formulated in ISA 720. Local adverse
effects were also more frequent and severe after the second and
third doses than after the first dose. In the EBV vaccine study,
while the vaccine was well tolerated, mild to moderate injection
site reactions occurred in 12 of the 14 subjects. In the melanoma
vaccine study [59], mild to moderate local reactions were reported
in all patients.
Homogenization is required to generate stable water-in-oil
emulsions of antigens formulated with ISA 720 [26]. This
procedure contrasts with the ease of generating oil-in-water
emulsions, e.g. RTS,S in ASO1 or 2, which can be formulated
by simply mixing at the point-of-injection. A consequence of the
need to pre-formulate MSP2-C1 in ISA 720 is the need to obtain
stability data on the formulated vaccine. This can be problematic
because of the extensive assay development that is required at an
early stage of vaccine development [26]. Physicochemical
analyses on the formulated vaccine and antigens extracted from
the emulsion carried out at CSL Ltd Melbourne on preclinical
batches of the vaccine prepared for toxicology tests indicated
that the emulsion was stable, and the antigens retained their
integrity for 18 months (data not shown). The same vaccine
batches were tested for immunogenic stability by immunizing
mice with three different antigen doses that were below the
threshold for a maximum response. The results from a test
carried out after 13 months storage of the preclinical batches
suggested a loss of immunogenicity (data not shown) and for this
reason the vaccine was unavailable for Cohort 2 to receive the
third vaccine dose. The same vaccine batches passed a
subsequent immunogenicity test, thus highlighting a problem
with using in vivo potency as a pass-fail criteria at this early stage
of vaccine development.
It is apparent from this study and a range of other human
clinical trials of recombinant proteins as malaria vaccine
candidates that eliciting a strong immune response is likely to be
of major importance in inducing vaccine-induced protection, and
that selection of an appropriate adjuvant is critical to ensuring that
an appropriate balance between reactogenicity and immunoge-
nicity is achieved. For example, it was only when RTS,S was
formulated in an oil-in-water emulsion containing the immune
stimulants monophosphoryl lipid A and QS21 that this anti-
sporozoite vaccine showed protective efficacy [60]. In addition,
vaccine-adjuvant formulations must meet stringent requirements
including stability and tolerable reactogenicity. Problems with the
selection and use of vaccine adjuvants for malaria have been
recently reviewed [61]. A significant development has been the
establishment of collaborative networks for sharing vaccine
adjuvants for high burden tropical disease, including malaria
[62,63].
The rationale for developing MSP2-C1 was the finding in the
Combination B trial that protection was ‘strain-specific’. There-
fore, antibody responses to the central dimorphic regions of both
types of MSP2 would be required to achieve efficacy against most
P. falciparum msp2 genotypes [23]. It was encouraging to find that
trial subjects had equally high antibody titers to both components
of MSP2-C1 and that these antibodies had ADCI activity against
parasites representative of the two MSP2 types. However, sero-
epidemiological studies have not clearly established that ‘allele-
specific’ anti-MSP2 antibodies are a component of naturally
acquired protective antibody responses [27,28,64], and some
antibodies with ADCI activity appear to recognize an epitope in
the conserved C-terminal region of MSP2 [38]. Consequently, it
will be important to compare the fine specificity of anti-MSP2
antibody responses induced by vaccination and infection, and
further studies are required to determine the relative importance
of antibodies to conserved and variable regions of MSP2 in
protecting against infection or disease.
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Figure S1 Lymphoproliferative responses to recombinant MSP2
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responses to recombinant MSP2 of the 3D7 and FC27 alleles.
Results are expressed as the stimulation index (SI), presented as
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Table S1 Two day 0 samples (marked with an asterisk) had
substantial ADCI activity (70% and 76% for 3D7), and two day
112 samples (marked with an asterisk) had relatively low activity
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